Form 4: RA Capital Management Significantly Increases Stake in Cidara Therapeutics

RA Capital Management, a major institutional investor and director, acquired over 2.2 million shares of Cidara Therapeutics common stock for $44 per share, boosting its beneficial ownership to over 3.3 million shares.

Summary

• RA Capital Management, L.P., along with its related entities and managing members Peter Kolchinsky and Rajeev Shah, reported a significant acquisition of Cidara Therapeutics, Inc. common stock.
• On June 26, 2025, 2,272,727 shares of common stock were acquired at a price of $44 per share.
• Following this transaction, the beneficial ownership of RA Capital Healthcare Fund, L.P. increased to 3,365,523 shares of common stock.
• The reporting persons, including RA Capital Management, RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev Shah, are identified as both Directors and 10% Owners of Cidara Therapeutics.
• Joshua Resnick, a Partner of RA Capital Management, also serves on Cidara Therapeutics' board of directors.

Sentiment

Score: 8

Explanation: The significant purchase of shares by a major institutional investor and director signals strong confidence in the company's value and future, which is a highly positive indicator for the market.

Positives

• A significant share purchase by a major institutional investor and director indicates strong confidence in the company's future prospects.
• The acquisition price of $44 per share suggests a valuation point considered attractive by a sophisticated investor.
• Increased alignment of interests between a major institutional shareholder/director and other shareholders.

Future Outlook

A Form 4 primarily reports a completed transaction and does not typically contain forward-looking statements or guidance from the issuer.

Industry Context

This transaction reflects an investment decision by a specialized healthcare fund (RA Capital) in a biotechnology company (Cidara Therapeutics). Such significant insider buying can signal confidence in the company's pipeline or strategic direction within the biotech sector, potentially influencing broader market perception.

Related Party Transactions

• The reported transaction is a related party transaction as RA Capital Management, L.P. and its affiliates are 10% owners and have directors serving on the board of Cidara Therapeutics, Inc.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• The transaction aligns the interests of a major institutional investor with those of other shareholders.

Key Dates

Recommendation

Keywords

Cidara Therapeutics, CDTX, RA Capital Management, Stock Purchase, Insider Buying, Form 4, Biotechnology, Healthcare Investment, Share Acquisition, Institutional Investor